Comstock Resources is a growing independent energy company engaged in the acquisition, development, production and exploration of oil and natural gas properties. As of December 31, 2014, the company owned interests in nearly 1,600 producing wells with an estimated 620 … Continue reading →

Glori Energy is an energy technology and oil production company leveraging its proprietary AERO™ technology to increase the amount of oil that can be produced from conventional wells. In addition to using the technology on its own U.S. oil fields, … Continue reading →

Solar3D, a provider of solar power solutions and the developer of a proprietary high efficiency solar cell, announced that it has inked a definitive agreement to acquire 100% of Elite Solar, a Durham, California-based solar systems provider. The purchase is … Continue reading →

Great Basin Scientific is a molecular diagnostics company developing, manufacturing and commercializing breakthrough chip-based technologies that enable cost-effective, reliable infectious disease testing. By focusing on affordability and ease-of-use, the company is working to make molecular testing available to every patient, … Continue reading →

Canadian biotech Aquinox Pharmaceuticals (NASDAQ: AQXP) created quite the industry buzz last week when the company reported positive mid-stage trial results for its bladder pain drug, AQX-1125. In addition to meeting secondary endpoints, the LEADERSHIP trial also demonstrated that a … Continue reading →

PEDEVCO is focused on acquiring and developing high growth energy projects, including shale oil and gas assets, in the United States. Though the company’s principal asset is its D-J Basin Asset located in the D-J Basin in Colorado, PEDEVCO last … Continue reading →

Successful Close of $41.4 Million Launches “The Vape Store” Retail Expansion One of the leading U.S. based distributors and retailers of e-cigs, e-liquids, e-hookahs and personal vaporizers, Vapor Corp. recently closed on a $41.4 million capital raise (NASDAQ: VPCOU). The … Continue reading →

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need. The company’s leading product candidate, Bremelanotide, is currently set to begin two phase III clinical … Continue reading →